Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Danburstotug by ImmuneOncia Therapeutics for Metastatic Melanoma: Likelihood of Approval
Danburstotug is under clinical development by ImmuneOncia Therapeutics and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase...